Background
==========

Breast cancer is the most common cancer among women worldwide. It accounts for 23% of all new cancers in women excluding cancers of the skin \[[@B1],[@B2]\]. Breast cancer is ranked as the most prevalent cancer among women in the Arab world \[[@B1]\]. Advances in diagnostic and treatment modalities have also resulted in increased survival. Thus, coping with breast cancer as a chronic disease is becoming a more common phenomenon.

In the Arab world, surgeons and oncologists dealing with breast cancer tend to believe that it presents at an earlier age with a more advanced stage at presentation \[[@B3]\]. This impression is particularly evident in Bahrain and other Gulf Cooperation Council \[[@B4]\] countries where women aged less than 40 years make up a larger percentage of total breast cancer cases than do their counterparts in Western countries \[[@B5],[@B6]\]. In addition, Bahraini women similar to other Arab women face cultural taboos surrounding breast cancer. Some families fear that their daughters will not be able to marry if a mother's diagnosis of breast cancer becomes known \[[@B7]\].

The increased survival of breast cancer patients, the younger age at diagnosis, and the unique set of cultural norms and values all suggest that information on quality of life (QoL) in this region may be specific and therefore important to both health care providers and patients. However, little information of this nature is available. This study aims to describe the quality of life of Bahraini women with breast cancer and to identify factors that may facilitate improvements in health care for breast cancer survivors in Bahrain.

Methods
=======

Setting
-------

Bahrain consists of an archipelago of islands located in the Arabian Gulf. It has a population of 1,106,509, of which 537,719(48.6%) are Bahrainis \[[@B8]\]. Bahrain has a national health service with care being free at the point of contact for Bahraini citizens. The main governmental hospital is Salmaniya Medical Complex which hosts the only oncology center in the country \[[@B4]\]. All diagnosed breast cancer cases are referred to this center for further adjuvant treatments.

Sampling and recruitment
------------------------

This is a descriptive cross sectional study. Bahraini women survivors of breast cancer diagnosed between 1^st^ January 1999 and 31^st^ December 2008 were identified from the Bahrain Cancer Registry. Non Bahraini women were excluded on the basis that quality of life may differ across different cultures and ethnic groupings. A sample size of 337 subjects was calculated to give 85% power at 5% significance with an estimated non response rate of 20%. A simple random sample was drawn from the Bahrain Cancer Registry using computer software. The researcher conducted a 10-minute interview with the participants after obtaining their consent in writing.

Study instruments
-----------------

A structured questionnaire collecting sociodemographic data, clinical information and quality of life data was used. Time elapsed since diagnosis was defined as: early after diagnosis (≤1 year since diagnosis), transitional period (\>1 and ≤5years since diagnosis) and long term survivors (\>5 to ≤10 years). Quality of life was assessed using the European Organization for Research and Treatment of Cancer QoL Cancer Specific Version (EORTC QLQ-C30, v.3.0) translated into Arabic and validated \[[@B9],[@B10]\]. Items explored by the EORTC QLQ-30 include nine domains: global health, physical, role, emotional, cognitive, social functioning, fatigue, nausea/vomiting, pain, and financial impact. We also used the QoL Breast Cancer Specific Version \[[@B9],[@B10]\] translated into Arabic. The EORTC QLQ-BR23 incorporates five domains: therapy side effects, arm symptoms, breast symptoms, body image, and sexual functioning.

Scores for these questions range between 0 and 100. For scales evaluating global health and function, a higher score represents higher level of functioning and health. For scales evaluating symptoms, a higher score indicates more problems and higher level of symptoms.

Ethical consideration
---------------------

Ethical approval was obtained from the ethics committees in the Royal College of Surgeons in Ireland-Medical University of Bahrain and the Ministry of Health in Bahrain.

Statistical analysis
--------------------

A supplemental scoring manual is provided with the questionnaire which was followed in the analysis \[[@B11]\]. The collected data were coded, entered and analyzed using the statistical package SPSS version 15.0. Relevant descriptive statistics were computed for all items. A higher score represents a "better" level of functioning, or a "worse" level of symptoms. The "Score" served as the dependent variable in the study for the purpose of data analyses. Sociodemographic data, cancer and treatment information represented the independent variables.

The equality of means across the categories of each categorical independent variable was tested using parametric tests (ANOVA and independent t-test). Non-parametric tests (Kruskal Wallis and Mann Whitney tests) were used if the statistical assumptions of using the parametric tests were violated. Additional exploration of the differences among means was determined by post hoc analysis.

As recommended by an empirical population based study \[[@B12]\], for the functional scales and the global quality of life, we defined subjects with problematic functioning as those who scored \<33.3%, while subjects in good condition scored ≥66.7%. For symptom scales, subjects scoring \< 33.3% were judged as having less severe symptoms, while those scoring ≥ 66.7% had more intense symptoms.

Linear Regression Modeling was used to build a predictive model to assess the significance of predictors and to compute the coefficient of determination. Global health, physical, emotional, cognitive and social functioning scores served as the dependent variables. All independent variables (age, duration since diagnosis, marital status, educational level, employment status, income, menopausal status, co-morbidities, pathological staging, history of metastases, lumpectomy, mastectomy, lymph node dissection , radiotherapy, hormonal therapy and chemotherapy) were categorized into two (yes and No) categories and served as predictors for the models. R squared was computed. A P-value \<0.05 was considered statistically significant.

Results
=======

Details of 337 Bahraini women with breast cancer were taken from the Bahrain Cancer Registry. Among the sample taken from the registry 18 had died and 66 were inaccessible. Seven were ineligible due to language barrier, deafness or wrong diagnosis, and seven refused to participate (reasons for not participating were lack of time, extreme anxiety, unwillingness to share their experience or not wanting to be reminded of their experience with cancer). Two hundred and thirty nine women consented to participate and were interviewed by the researcher (recruitment rate 71%).

Characteristics of the study sample
-----------------------------------

The characteristics of the sample are presented in Table [1](#T1){ref-type="table"}. The mean and median ages of participants were 50.2 (SD ± 11.1) and 48.0 years respectively. Mean time elapsed since diagnosis was 4.22 (SD ± 2.69) years.

###### 

Characteristics of the study population N = 239

  -------------------------------------------------------
  **Characteristic**                 **No.**     **%**
  ---------------------------------- --------- ----------
  **Age n = 239**                                   

  **≤50 year**                       **137**    **57.3**

  **\>50 years**                     **102**    **42.7**

  **Time since diagnosis n = 239**                  

  **Early diagnosed**                **35**     **14.6**

  **Transitional period**            **128**    **53.6**

  **Long term survivors**            **76**     **31.8**

  **Educational level n = 236**                     

  **Illiterate**                     **60**     **25.4**

  **Primary**                        **30**     **12.7**

  **Intermediate**                   **23**     **9.7**

  **High school/diploma**            **81**     **34.4**

  **College graduate**               **42**     **17.8**

  **Employment n = 236**                            

  **Yes**                            **50**     **21.2**

  **No**                             **146**    **61.9**

  **Retired**                        **40**     **16.9**

  **Monthly income n = 235**\        \             \
  **\<500**                          **132**    **56.2**

  **500**--**1000**                  **57**     **24.3**

  **\> 1000**                        **46**     **19.5**

  **Menopausal status n = 236**                     

  **Premenopause**                   **110**    **46.6**

  **Perimenopause**                  **36**     **15.3**

  **Postmenopause**                  **90**     **38.1**

  **Pathological staging n = 134**                  

  **Stage 0 and I**                  **40**     **29.9**

  **Stage II**                       **60**     **44.8**

  **Stage III and IV**               **34**     **25.3**

  **Distant metastasis n = 236**                    

  **Yes**                            **17**     **7.2**

  **No**                             **219**    **92.8**

  **Treatment modality n = 236**                    

  **Lumpectomy**                     **121**    **51.3**

  **Mastectomy**                     **118**    **50.0**

  **Lymph node dissection**          **200**    **85.1**

  **Chemotherapy**                   **190**    **80.5**

  **Radiotherapy**                   **198**    **83.9**

  **Hormonal therapy**               **164**    **69.8**
  -------------------------------------------------------

Profile of quality of life scale scores
---------------------------------------

Participants had a mean score for global health of 63.9 (95% CI 61.2-66.6). Among functional scales, social functioning scored the highest (77.5 \[95% CI 73.65-81.38\]) whereas emotional functioning scored the lowest (63.4 \[95% CI 59.12-67.71\]).

The most distressing symptom on the symptom scales was fatigability (Mean 35.2 \[95% CI 31.38-39.18\]) followed by sleep disturbance and pain (Table [2](#T2){ref-type="table"}). Using the disease specific tool it was found that sexual functioning scored the lowest (Mean 25.9 \[95% CI 70.23-77.90\]) indicating poor functioning whereas body image scored the highest (Mean 75.64 \[95% CI 71.79-79.48\]). On the symptom scale, upset due to hair loss scored the highest (Mean 46.3 \[95% CI 37.82-54.84\]) indicating worse functioning followed by arm symptoms (Mean 36.58 \[95% CI 32.50-40.65\]).

###### 

Mean score of all items in QLQ-C30 and QLQ-BR23 (N = 239)

  **Variables**                    **N**    **No. of items**    **Mean (SD)**    **95% CI**         **N (%) scoring \<33.3)**^**a**^   **N (%) scoring ≥66.7)**^**a**^
  ------------------------------ --------- ------------------ ------------------ ----------------- ---------------------------------- ---------------------------------
  **QLQ-C30**                                                                                                                                          
  **Global health status/QoL**    **238**        **2**         **63.93(21.34)**  **61.21-66.66**              **13(5.4)**                       **92(38.5)**
  **Functional scales**^**b**^                                                                                                                         
  **Physical functioning**        **239**        **5**         **74.92(21.69)**  **72.15-77.68**               **9(3.8)**                       **154(64.4)**
  **Role functioning**            **237**        **2**         **68.84(35.96)**  **64.24-73.44**              **33(13.8)**                      **132(55.2)**
  **Emotional functioning**       **236**        **4**         **63.41(33.46)**  **59.12-67.71**              **52(21.8)**                      **118(49.4)**
  **Cognitive functioning**       **238**        **2**         **73.38(29.87)**  **69.57-77.20**              **24(10.0)**                      **140(58.6)**
  **Social functioning**          **238**        **2**         **77.52(30.27)**  **73.65-81.38**              **21(8.8)**                       **152(63.6)**
  **Symptom scales**^**c**^                                                                                                                            
  **Fatigue**                     **239**        **3**         **35.28(30.62)**  **31.38-39.18**             **117(49.0)**                      **39(16.3)**
  **Nausea and vomiting**         **238**        **2**         **10.29(30.77)**  **6.36-14.22**              **208(87.0)**                       **9(3.8)**
  **Pain**                        **238**        **2**         **29.97(31.23)**  **25.98-33.96**             **135(56.5)**                      **31(13.0)**
  **Dyspnoea**                    **239**        **1**         **20.22(30.32)**  **16.35-24.08**             **149(62.3)**                       **15(6.3)**
  **Sleep disturbance**           **239**        **1**         **30.12(39.29)**  **25.11-35.13**             **136(56.9)**                      **42(17.6)**
  **Appetite loss**               **239**        **1**         **13.38(27.62)**  **9.86-16.90**              **185(77.4)**                       **11(4.6)**
  **Constipation**                **239**        **1**         **17.99(30.66)**  **14.08-21.89**             **163(68.2)**                       **18(7.5)**
  **Diarrhea**                    **239**        **1**         **6.83(18.95)**   **4.41-9.24**               **205(85.8)**                       **4(1.7)**
  **Financial impact**            **239**        **1**         **34.58(42.26)**  **29.20-39.97**             **130(54.4)**                      **57(23.8)**
  **QLQ-BR23**                                                                                                                                         
  **Functional scales**^**b**^                                                                                                                         
  **Body image**                  **234**        **4**         **75.64(29.86)**  **71.79-79.48**              **24(10.0)**                      **160(66.9)**
  **Sexual functioning**          **234**        **2**         **25.92(29.77)**  **70.23-77.90**              **10(4.2)**                       **129(54.0)**
  **Sexual enjoyment**            **116**        **1**         **48.56(32.12)**  **45.52-57.34**              **16(6.7)**                        **23(9.6)**
  **Future perspective**          **236**        **1**         **61.29(39.37)**  **56.25-66.34**              **43(18.0)**                      **105(43.9)**
  **Symptom scales**^**c**^                                                                                                                            
  **Systemic side effect**        **236**        **7**         **19.27(17.76)**  **16.98-21.55**             **187(78.2)**                       **4(1.7)**
  **Breast symptoms**             **236**        **4**         **13.66(18.06)**  **11.34-15.98**             **195(81.6)**                       **4(1.7)**
  **Arm symptoms**                **236**        **3**         **36.58(31.76)**  **32.50-40.65**             **113(47.3)**                      **34(14.2)**
  **Upset by hair loss**          **100**        **1**         **46.33(42.87)**  **37.82-54.84**              **38(15.9)**                      **32(13.4)**

^a^For functional scales, subjects scoring \< 33.3% have problems; those scoring ≥ ⊠66.7% have good functioning. For symptom scales/symptoms, subjects scoring \< 33.3% have good functioning; those scoring = 66.7% have problems.

^b^For functional scales, higher scores indicate better functioning.

^c^For symptom scales, higher scores indicate worse functioning.

Factors associated with QoL scale scores
----------------------------------------

### Global health and Functional scale in QLO-C30

There were significant differences in the global health means across categories of marital status (P =0.041), menopausal status (P =0.016), history of metastases (P = 0.016), monthly income (P =0.036) and type of surgery (P =0.026 and 0.017 for mastectomy and lumpectomy respectively). Post hoc analysis results revealed that subjects who were not married, premenopausal, with no history of metastases, have high income and who were treated by lumpectomy tended to have better global health related quality of life (Table [3](#T3){ref-type="table"}).

###### 

**Global health and functional scales in QLQ-C30 by independent variables (N = 239)**^**a**^

    **Characteristic**     **Global health /QoL Mean(SD)**   **Functional scales in QLQ-C30**^**b**^                                                 
  ----------------------- --------------------------------- ----------------------------------------- -------------- --------------- --------------- --------------
            Age                                                                                                                                             
         ≤50 year                    67.7(20.04)                          77.37(20.47)                 69.97(37.06)   60.30(33.32)    70.31(30.42)    76.03(32.89)
        \>50 years                  58.90(22.07)                          71.63(22.91)                 67.32(34.55)   67.57(33.37)    77.55(28.71)    79.53(26.33)
          P-value                       0.147                                 0.271                       0.176           0.710           0.412          0.005
   Time since diagnosis                                                                                                                                     
      Early diagnosed               61.66(27.20)                          74.09(24.02)                 58.82(40.04)   55.00(38.57)    70.95(32.92)    70.47(39.41)
    Transitional period             62.76(20.99)                          73.69(21.30)                 66.66(36.06)   64.37(33.02)    74.93(29.76)    76.37(28.90)
    Long term survivors             67.00(18.65)                          77.36(21.30)                 76.97(32.54)   65.76(31.44)    71.92(28.83)    82.67(27.14)
          P-value                       0.478                                 0.400                       0.034           0.461           0.574          0.179
      Marital status                                                                                                                                        
          Single                    68.11(18.05)                          73.91(23.69)                 61.59(40.95)   59.78(39.22)    69.56(31.24)    66.66(41.43)
          Married                   65.56(19.97)                          77.83(17.98)                 70.96(34.17)   63.95(32.00)    74.84(28.92)    81.04(25.86)
         Divorced                   58.33(27.34)                          62.85(29.31)                 50.00(44.61)   55.95(38.31)    57.14(34.41)    70.23(37.65)
          Widowed                   56.04(24.45)                          67.50(28.08)                 69.58(36.57)   66.04(35.37)    75.41(30.65)    71.79(35.28)
          P-value                       0.041                                 0.123                       0.216           0.780           0.205          0.371
     Educational level                                                                                                                                      
        Illiterate                  61.25(24.29)                          73.11(21.85)                 67.77(33.59)   75.00(30.66)    78.24(28.74)    77.40(24.32)
          Primary                   54.16(25.21)                          60.66(27.14)                 57.77(42.82)   54.72(32.65)    75.55(30.86)    77.22(30.47)
       Intermediate                 68.56(23.13)                          78.55(23.09)                 64.39(42.81)   65.94(36.31)    71.73(33.87)    71.01(38.34)
        High school                 66.87(17.12)                          79.17(18.63)                 73.04(33.18)   59.77(34.25)    71.19(29.46)    79.21(33.17)
     College graduate               65.27(65.27)                          76.34(76.34)                 70.73(70.73)   58.33(58.33)    69.44(69.44)    77.38(77.38)
         P -value                       0.059                                 0.009                       0.548           0.009           0.284          0.535
        Employment                                                                                                                                          
            Yes                     67.83(15.88)                          76.53(21.81)                 73.00(36.24)   60.20(32.46)    72.00(29.82)    78.00(31.66)
            No                      62.47(23.53)                          73.51(21.89)                 65.52(36.75)   64.00(33.58)    73.44(30.26)    74.48(30.68)
          Retired                   62.91(18.58)                          76.83(21.08)                 74.12(32.58)   64.37(35.45)    74.16(29.46)    87.08(26.00)
          P-value                       0.428                                 0.516                       0.196           0.559           0.924          0.024
      Monthly income                                                                                                                                        
           \<500                    60.55(23.06)                          71.46(23.62)                 63.61(36.96)   62.05(34.81)    72.39(30.22)    71.75(32.61)
         500--999                   67.10(17.35)                          78.59(18.88)                 69.34(37.16)   65.02(32.54)    75.73(29.22)    79.82(30.00)
          \>1000                    68.47(19.79)                          79.13(17.92)                 82.60(27.65)   64.13(32.00)    72.82(30.70)    90.94(17.46)
          P-value                       0.036                                 0.087                       0.005           0.974           0.818          0.001
     Menopausal status                                                                                                                                      
       Premenopause                 67.20(20.32)                          76.84(20.34)                 67.43(37.60)   59.49(34.30)    69.54(31.75)    74.24(33.45)
       Perimenopause                67.82(16.07)                          77.77(20.15)                 71.75(35.37)   62.96(33.65)    69.90(30.03)    83.79(28.86)
       Postmenopause                57.77(23.19)                          70.88(23.51)                 68.51(34.74)   67.97(32.41)    79.21(26.74)    78.65(26.58)
          P-value                       0.016                                 0.142                       0.831           0.123           0.057          0.268
   Pathological staging                                                                                                                                     
       Stage 0 and I                66.87(17.65)                          74.33(22.26)                 66.66(36.98)   59.58(31.72)    69.58(32.66)    82.08(28.59)
         Stage II                   65.55(23.14)                          74.55(23.43)                 69.49(35.17)   64.58(32.92)    77.50(28.59)    72.31(30.88)
     Stage III and IV              58\. 08 (26.47)                        68.23(23.60)                 50.98(41.83)   53.67 (37.67)   67.15 (28.86)   65.68(34.55)
          P-value                       0.295                                 0.411                       0.072           0.313           0.151          0.054
        Metastases                                                                                                                                          
            Yes                     52.45(19.93)                          55.29(24.69)                 26.47(38.66)   42.64(37.71)    55.88(36.29)    57.29(37.00)
            No                      64.56(21.25)                          76.22(20.76)                 71.81(33.79)   64.89(32.77)    74.61(29.03)    78.84(29.41)
          P value                       0.016                                 0.001                       0.000           0.016           0.024          0.009
        Mastectomy                                                                                                                                          
            Yes                     60.47(22.93)                    71.86(22.81)777.57(20.22)          64.22(37.31)   61.49(34.97)    74.64(28.91)    73.50(30.57)
            No                      66.87(19.22)                                                       72.74(34.43)   65.02(32.18)    71.89(30.94)    81.21(29.84)
          P-value                       0.026                                 0.053                       0.053           0.536           0.613          0.010
        Lumpectomy                                                                                                                                          
            Yes                     67.08(19.26)                          77.68(20.36)                 72.86(34.16)   65.48(31.92)    71.90(30.58)    81.40(29.59)
            No                      60.14(22.88)                          71.59(22.70)                 63.86(37.59)   60.91(35.23)    74.70(29.26)    73.09(30.76)
          P-value                       0.017                                 0.033                       0.048           0.435           0.514          0.007
   Lymph node dissection                                                                                                                                    
            Yes                     63.44(21.19)                          75.50(21.28)                 67.92(36.40)   62.64(33.70)    73.11(29.94)    77.47(30.50)
            No                      65.00(22.75)                          70.47(24.10)                 70.95(34.61)   65.71(33.07)    73.33(30.30)    77.14(30.54)
          P-value                       0.771                                 0.255                       0.753           0.545           0.937          0.776
       Chemotherapy                                                                                                                                         
            Yes                     64.41(20.95)                          76.00(20.73)                 67.28(37.02)   61.31(34.19)    73.54(29.26)    77.16(30.70)
            No                      60.68(22.88)                          69.42(24.88)                 73.55(31.73)   71.19(30.00)    72.10(32.78)    78.26(29.36)
          P-value                       0.358                                 0.122                       0.472           0.080           0.828          0.895
       Radiotherapy                                                                                                                                         
            Yes                     64.25(21.06)                          75.82(21.94)                 69.72(36.11    63.77(33.12)    73.40(29.60)    79.10(29.48)
            No                      60.74(22.83)                          68.94(19.68)                 62.28(35.65)   60.58(36.25)    72.52(31.96)    68.42(33.73)
          P-value                       0.538                                 0.024                       0.172           0.779           0.992          0.043

^a^P-value based on Kruskal Wallis or Mann Whitney tests.

^b^For functional scales, higher scores indicate better functioning.

Differences in the physical functioning means were observed across categories of educational level (P =0.009), history of metastases (P =0.001) and history of lumpectomy (P =0.033). Post hoc analysis showed that educated subjects who finished high school and had conservative breast surgery (lumpectomy) had better functioning on the physical scale.

### Symptom scales in QLQ-C30

With the exception of financial impact, there were significant differences in all symptom scales across categories of metastasis. Post hoc analysis showed that women with metastases experienced worse symptoms. Differences in pain means were seen among age (P = 0.003), menopause (P = 0.003) and metastases categories (P = 0.001). Post hoc analysis revealed that younger, pre-menopausal women and those with a history of metastases experienced more pain.

### Functional and symptom scales in QLQ-BR 23

Differences in means of body image were significant among categories of educational level (P = 0.029), and mastectomy (P = 0.022). Post hoc analysis showed that women who had undergone mastectomy and were highly educated tended to have poorer body image (Table [4](#T4){ref-type="table"}). Better sexual functioning was observed for married women (P \< 0.001), high income (P \< 0.001), long term survivors (P = 0.027).

###### 

**Functional and symptom scales in QLQ-BR23**^**a**^

                           **Functional scales in BR 23**^**b**^   **Symptom scale in BR 23**^**c**^                                                                                
  ----------------------- --------------------------------------- ----------------------------------- -------------- --------------- --------------- -------------- --------------- --------------
  Age                                                                                                                                                                                      
  ≤50 year                             72.53(31.24)                          29.25(29.88)              48.91(34.02)   55.55(39.69)    20.07(18.66)    16.35(19.75)   39.09(31.74)    51.41(43.47)
  \>50 years                           79.88(27.45)                          21.38(29.16)              47.86(28.40)   68.97(37.78)    18.19(16.52)    10.06(14.87)   33.22(31.64)    39.02(41.43)
  P-value                                  0.134                                 0.744                    0.103           0.257           0.453          0.034           0.983          0.257
  Time since diagnosis                                                                                                                                                                     
  Early diagnosed                      65.47(37.33)                          18.09(27.52)              55.55(35.76)   44.76(44.23)    25.85(19.77)    20.95(22.17)   43.80(32.44)    70.83(34.15)
  Transitional period                  75.67(30.32)                          23.65(27.71)              44.44(27.89)   63.22(39.06)    17.83(17.28)    11.11(14.45)   32.18(29.57)    41.49(42.23)
  Long term survivors                  80.33(23.83)                          33.33(32.76)              52.27(36.22)   65.77(35.92)    18.59(17.10)    14.55(20.50)   40.59(34.19)    41.90(44.53)
  P-value                                  0.292                                 0.027                    0.338           0.037           0.065          0.044           0.093          0.035
  Marital status                                                                                                                                                                           
  Single                               74.63(34.31)                           5.07(16.99)                66.66(−)     60.86(44.55)    25.05(25.32)    13.40(24.71)   35.26(29.89)    33.33(40.20)
  Married                              73.88(29.97)                          37.47(29.33)              48.83(32.03)   61.63(38.46)    16.96(14.81)    14.30(17.74)   38.22(31.81)    43.28(43.03)
  Divorced                             80.95(27.62)                           4.76(12.10)                0.00(−)      52.38(46.61)    30.95(20.09)    18.45(16.72)   35.71(31.17)    86.66(32.20)
  Widowed                              81.25(27.59)                           0.00 (0.00)                   \-        63.33(38.34)    20.95(20.51)    9.58(15.04)    31.11(33.30)    43.33(38.65)
  P-value                                  0.446                                 0.000                    0.288           0.877           0.060          0.046           0.484          0.020
  Educational level                                                                                                                                                                        
  Illiterate                           82.32(27.79)                          24.71(31.87)              52.56(30.07)   75.00(33.96)    16.06(14.95)    9.72(15.65)    32.03(31.36)    28.07(40.46)
  Primary                              78.88(25.49)                          11.11(22.46)              33.33(30.86)   57.77(40.05)    21.11(17.58)    13.61(20.81)   43.70(34.39)    71.42(40.49)
  Intermediate                         71.01(33.32)                          28.98(32.26)              52.77(30.01)   63.76(44.84)    17.59(20.47)    16.30(16.94)   35.26(34.26)    75.00(38.83)
  High school/diploma                  75.30(30.46)                          26.95(27.20)              44.20(34.46)   55.14(39.84)    20.92(18.87)    15.12(18.49)   36.35(30.73)    40.47(41.99)
  College                              67.26(31.20)                          34.52(31.96)              55.55(30.56)   54.76(38.83)    20.18(17.90)    15.07(18.88)   39.15(31.44)    55.07(42.17)
  P -value                                 0.029                                 0.015                    0.417           0.026           0.432          0.490           0.067          0.021
  Employment                                                                                                                                                                               
  Yes                                  76.19(28.31)                          29.25(30.90)              53.33(34.69)   50.66(38.82)    20.47(19.76)    16.66(20.68)   38.00(30.12)    51.38(40.50)
  No                                   75.57(30.84)                          24.94(29.14)              47.29(31.69)   63.69(38.93)    18.42(17.08)    13.47(18.10)   35.31(32.35)    42.30(43.34)
  Retired                              75.20(28.77)                          25.41(31.12)              47.05(31.31)   65.83(40.28)    20.83(17.80)    10.62(13.73)   39.44(32.11)    50.72(45.91)
  P-value                                  0.885                                 0.697                    0.756           0.070           0.683          0.425           0.610          0.558
  Monthly income                                                                                                                                                                           
  \<500                                75.38(30.40)                          17.30(25.95)              42.85(30.42)   60.60(40.52)    21.51(17.70)    13.63(18.34)   35.35(30.44)    47.27(42.88)
  500--999                             75.00(29.37)                          35.38(31.82)              50.00(35.30)   61.40(40.72)    17.62(20.91)    14.91(17.23)   37.42(33.89)    43.05(43.38)
  \>1000                               78.62(27.97)                          78.62(30.19)              55.95(30.16)   63.76(35.01)    15.21(12.32)    10.86(16.18)   37.68 (32.32)   48.33(45.20)
  P-value                                  0.780                                 0.000                    0.231           0.965           0.035          0.354           0.901          0.906
  Menopausal status                                                                                                                                                                        
  Premenopause                         71.43(31.97)                          30.00(29.93)              48.48(34.68)   56.36(39.29)    19.56(17.73)    17.27(20.05)   40.30(31.92)    48.97(43.08)
  Perimenopause                        77.31(28.28)                          26.85(29.08)              49.01(26.66)   56.48(41.26)    20.50(20.22)    15.74(19.08)   34.87(32.00)    54.76(46.42)
  Postmenopause                        80.20(27.22)                          20.45(29.33)              48.48(30.15)   69.25 (37.80)   18.408(16.88)   8.42(13.42)    32.71(31.31)    39.81(42.02)
  P-value                                  0.091                                 0.049                    0.985           0.047           0.876          0.001           0.169          0.473
  Pathological staging                                                                                                                                                                     
  Stage 0 and I                        76.28(28.26)                          22.64(26.34)              43.75(33.81)   60.68(41.09)    19.65(13.69)    17.09(18.72)   42.16(32.16)    56.25(48.25)
  Stage II                             78.67(29.57)                          25.42(28.42)              47.31(33.08)   61.58(40.02)    20.33(19.24)    14.40(20.63)   36.34(31.21)    33.33(36.00)
  Stage III and IV                     61.51(36.17)                          20.09(25.87)              48.88(27.79)   52.94(45.03)    24.36(21.51)    15.93(19.82)   36.92(34.46)    50.00(40.82)
  P-value                                  0.052                                 0.761                    0.884           0.609           0.691          0.560           0.363          0.225
  Metastases                                                                                                                                                                               
  Yes                                  71.56(35.36)                          14.70(24.21)              33.33(36.51)   47.05(39.19)    36.13(29.26)    28.43(25.52)   54.24(35.54)    43.33(44.58)
  No                                   75.96(29.46)                          26.80(30.03)              49.39(31.84)   62.40(39.26)    17.95(15.91)    12.51(16.90)   35.21(31.12)    46.81(43.14)
  P-value                                  0.585                                 0.117                    0.299           0.131           0.013          0.008           0.033          0.831
  Mastectomy                                                                                                                                                                               
  Yes                                  70.01(33.22)                          26.35(29.13)              47.77(32.10)   62.14(40.63)    19.69(19.06)    14.33(19.21)   37.75(31.66)    46.80(43.21)
  No                                   81.26(24.97)                          25.49(30.52)              49.40(32.40)   60.45(38.22)    18.84(16.41)    12.99(16.89)   35.40(31.95)    46.15(43.36)
  P-value                                  0.022                                 0.665                    0.768           0.684           0.964          0.827           0.499          0.965
  Lumpectomy                                                                                                                                                                               
  Yes                                  80.76(24.91)                          24.58(30.47)              48.80(33.61)   60.60(38.49)    18.80(16.26)    13.42(17.98)   35.44(31.76)    45.28(43.40)
  No                                   70.24(33.58)                          27.33(29.09)              48.33(30.94)   60.02(40.43)    19.75(19.26)    13.98(18.22)   37.77(31.86)    47.82(43.12)
  P-value                                  0.059                                 0.322                    0.933           0.736           0.931          0.846           0.529          0.788
  Lymph node dissection                                                                                                                                                                    
  Yes                                  74.53(30.39)                          25.75(29.59)              47.81(33.38)   59.50(39.52)    19.59(17.60)    13.12(17.15)   37.22(31.87)    48.23(43.18)
  No                                   81.42(26.66)                          25.71(30.87)              52.08(24.24)   70.47(37.72)    17.50(19.07)    15.71(22.11)   32.06(31.28)    38.46(42.70)
  P-value                                  0.249                                 0.884                    0.754           0.115           0.406          0.728           0.348          0.434
  Chemotherapy                                                                                                                                                                             
  Yes                                  73.89(30.73)                          27.03(29.70)              48.14(33.40)   60.17(39.97)    20.10(18.26)    14.29(18.49)   37.95(31.22)    46.89(42.58)
  No                                   82.78(25.05)                          21.37(29.95)              50.98(23.91)   65.94(36.84)    15.76(15.15)    11.05(16.10)   30.91(33.69)    43.58(47.88)
  P-value                                  0.071                                 0.161                    0.781           0.387           0.144          0.213           0.097          0.806
  Radiotherapy                                                                                                                                                                             
  Yes                                  76.56(29.28)                          26.14(30.12)              50.34(31.83)   61.11(39.27)    18.37(16.86)    13.25(17.79)   36.64(31.58)    43.20(42.30)
  No                                   70.72(32.78)                          24.77(28.22)              38.88(32.83)   62.28(40.39)    24.06(21.58)    15.78(19.54)   36.25(33.15)    61.11(44.64)
  P-value                                  0.335                                 0.970                    0.193           0.837           0.220          0.389           0.869          0.117

^a^P-value based on Kruskal Wallis or Mann Whitney tests.

^b^For functional scales, higher scores indicate better functioning.

^c^For symptom scales, higher scores indicate worse functioning.

More intense upset by hair loss was noted among women who were recently diagnosed (P = 0.035); divorced as opposed to single women (P = 0.020) and those who had intermediate education (P = 0.021).

Women who had metastases complained of more severe systemic side effects (P = 0.013), breast (P = 0.008) and arm symptoms (P = 0.033).

Women who were recently diagnosed were more worried about their future (P = 0.037), and complained of more breast symptoms (P = 0.044) and were more upset by the loss in their hair (P = 0.035).

Predictors of quality of life
-----------------------------

The predictors explained 24% of the variation in global health (R-squared = 0.24). The predictors which had a significant effect on global health given the other predictors in the model were staging of the disease (P = 0.005) and menopausal status (P = 0.031) (Table [5](#T5){ref-type="table"}). The same model was built for every domain in QLQ-C30. Metastasis was a significant predictor in the physical and role functioning models (P = 0.002 and 0.003) respectively. Co-morbidities and chemotherapy were significant predictors in role functioning model (P = 0.032 and 0.009) respectively.

###### 

Final linear regression model with parameter estimates for QLQ functional scales

                               **Global QoL score**   **Physical functioning**   **Role functioning**   **Emotional functioning**   **Cognitive functioning**   **Social functioning**                                             
  --------------------------- ---------------------- -------------------------- ---------------------- --------------------------- --------------------------- ------------------------ -------- ------- -------- ------- -------- ---------
  Constant                            63.298                  \<0.001                   36.082                    0.024                        56                       0.032            77.93    0.001   71.909   0.001   41.898    0.047
  **Age \> 50**                       −0.007                   0.956                    0.187                     0.103                       0.022                     0.848            2.757    0.007   0.135    0.285     0       0.999
  No = 0                                                                                                                                                                                                                                
  Yes = 1                                                                                                                                                                                                                               
  **Married**                         0.116                    0.231                    0.129                     0.168                       0.076                     0.434            0.837    0.404    0.11    0.288    0.35    \<0.001
  No = 0                                                                                                                                                                                                                                
  Yes = 1                                                                                                                                                                                                                               
  **Education**                       −0.024                   0.844                    0.192                     0.103                      −0.021                     0.861            −0.25    0.803   −0.112   0.384   −0.137    0.244
  No = 0                                                                                                                                                                                                                                
  Yes = 1                                                                                                                                                                                                                               
  **Employment**                      −0.018                   0.853                    −0.109                    0.252                      −0.078                     0.429            −0.863   0.39    0.036    0.732   −0.054    0.571
  No = 0                                                                                                                                                                                                                                
  Yes = 1                                                                                                                                                                                                                               
  **High Income**                     0.109                     0.29                    0.086                     0.391                       0.171                     0.098            1.612    0.11    0.101    0.361    0.25     0.014
  No = 0                                                                                                                                                                                                                                
  Yes = 1                                                                                                                                                                                                                               
  **Menopause**                       −0.259                   0.031                    −0.128                    0.269                       0.068                     0.565            −0.621   0.536   −0.01    0.934   0.034     0.769
  No = 0                                                                                                                                                                                                                                
  Yes = 1                                                                                                                                                                                                                               
  **Advanced stage**                  −0.275                   0.005                    −0.061                    0.516                      −0.189                     0.051            −0.54    0.59    −0.106   0.304   −0.156    0.101
  No = 0                                                                                                                                                                                                                                
  Yes = 1                                                                                                                                                                                                                               
  **Late survivors**                  −0.105                   0.263                    −0.021                    0.819                       0.071                     0.447            0.861    0.391   −0.067   0.506   −0.015    0.873
  No = 0                                                                                                                                                                                                                                
  Yes = 1                                                                                                                                                                                                                               
  **Comorbidities**                   −0.027                   0.783                    −0.046                    0.63                        0.054                      0.58            −2.171   0.032   0.037    0.725   −0.088    0.363
  No = 0                                                                                                                                                                                                                                
  Yes = 1                                                                                                                                                                                                                               
  **Metastases**                      −0.086                   0.385                    −0.297                    0.002                      −0.303                     0.003            −1.691   0.094   −0.174    0.1    −0.103    0.285
  No = 0                                                                                                                                                                                                                                
  Yes = 1                                                                                                                                                                                                                               
  **Lumpectomy**                      0.321                    0.205                     0.45                     0.068                       0.15                      0.551            0.746    0.457   0.072    0.789   0.265     0.282
  No = 0                                                                                                                                                                                                                                
  Yes = 1                                                                                                                                                                                                                               
  **Mastectomy**                      0.319                    0.203                    0.417                     0.087                       0.109                     0.659            0.938    0.35    0.128    0.632   0.166     0.495
  No = 0                                                                                                                                                                                                                                
  Yes = 1                                                                                                                                                                                                                               
  **Lymph node dissection**           −0.068                   0.461                    0.052                     0.559                       −0.01                     0.917            −1.763   0.081   −0.013   0.892   0.031     0.731
  No = 0                                                                                                                                                                                                                                
  Yes = 1                                                                                                                                                                                                                               
  **Chemotherapy**                    −0.033                   0.743                    −0.07                     0.466                      −0.061                     0.535            −2.646   0.009   −0.095   0.371   −0.043    0.654
  No = 0                                                                                                                                                                                                                                
  Yes = 1                                                                                                                                                                                                                               
  **Radiotherapy**                    −0.085                   0.376                    0.159                     0.089                       0.061                     0.524            0.139    0.89    −0.046   0.65    0.083     0.377
  No = 0                                                                                                                                                                                                                                
  Yes = 1                                                                                                                                                                                                                               
  **Hormonal therapy**                0.036                    0.688                    −0.063                    0.464                      −0.178                     0.047            −0.76    0.449    0.04    0.677   0.008     0.931
  No = 0                                                                                                                                                                                                                                
  Yes = 1                                                                                                                                                                                                                               
  **R squared**                        0.24                     0.28                     0.25                     0.25                        0.132                     0.281                                                      
  **P-value**                         0.015                    0.002                    0.009                     0.01                        0.455                     0.002                                                      

Discussion
==========

This is the first study to assess quality of life of breast cancer survivors in Bahrain and indicates that Bahraini women with breast cancer have average to good quality of life functioning and low to average symptoms experience. Not surprisingly, the presence of metastases, advanced staging, having had a mastectomy as opposed to lumpectomy and the shorter time elapsed since diagnosis had a major effect across all the domains of quality of life of breast cancer survivors.

Comparison with previous literature
-----------------------------------

Our results were largely comparable to other Western and Asian studies \[[@B13]-[@B15]\]. However, there are specific domains that showed lower scores which could be related to socio-cultural and religious aspects.

The global health score obtained in this study from Bahraini breast cancer survivors (63.9) is similar to that obtained in other Western and Asian studies such as South Korea (66.5), United Kingdom (66.8 and 69.8) and Germany (65.5) \[[@B13]-[@B15]\]. This study was also similar to other studies in Europe and Asia in showing that the poorest functioning in terms of symptoms was for fatigue followed by sleep disturbance, pain, hair loss and arm symptoms \[[@B10],[@B13]-[@B19]\].

Within this region, Bahraini women with breast cancer have a lower quality of life than their counterparts in the United Arab Emirates (74.6) but higher than Kuwait (45.0) and Iran (32.0) \[[@B10],[@B16],[@B17]\]. However, caution has to be used in comparing data from these studies as the base populations vary in terms of age of participants, time elapsed since diagnosis and the staging of disease.

It is of note that global quality of life amongst Bahraini women was comparable with other studies despite the limited psychological support for breast cancer survivors in the Bahraini health care system. It may be that Bahraini women receive psychological support through other means such as the family or the wider society \[[@B20]\]. It could also be that participants in this study had greater difficulty understanding the meaning of quality of life and consequently responded to questions more positively.

There is a substantial body of literature documenting that comparison of quality of life data should go beyond the usual presentation of observed mean scores \[[@B12],[@B21]\]. Various approaches have been recommended but so far there is no comprehensive approach suitable for the interpretation of quality of life results from a global perspective. Some of the suggested approaches are: using population-based reference values \[[@B12],[@B22]\]; reporting the minimum important difference (mostly a difference of 10 points or more was used to define a clinically relevant change) \[[@B23]\]; and defining a particular proportion of patients achieving a predefined degree of benefit \[[@B23]\]. Although these methods are meaningful, they are arbitrary and subject to individual's opinions. In this study we used 10 points as the minimum important difference and the proportion of patients achieving a particular degree of benefit as two methods of interpreting our quality of life data. For example, although the mean score for global QLQ -- C30 indicated average to good functioning, only a third (38.5%) of participants met the 66.7% criterion for good functioning. Using the same criteria, poorer functioning for global quality of life was reported in Kuwait (10.9% scored ≥ 66.7 on the same scale) \[[@B17]\]. Problematic functioning for global quality of life in a Korean study was reported by 21.5% of participants \[[@B13]\], in Kuwait by 6.2% \[[@B17]\] and in our study by only 5.4%. This analysis is not available in many studies so comparison is not always possible. One should be cautious interpreting this finding because, while the sample in our study was chosen at random from a national cancer registry, the Korean study was hospital based and the Kuwaiti authors used a convenience sample. Another factor to mention is the higher mean age of our participants (50.2) compared to both studies (Range 46.6- 48.3).

Similar to many other studies \[[@B24],[@B25]\], women showed an average performance on most functional scales except for sexual functioning and enjoyment which demonstrated poor functioning. Reasons suggested for disturbed sexual function include low self esteem, hair loss, abrupt menopause, vaginal dryness, partner\'s difficulty understanding one's feelings and body image problems \[[@B24],[@B25]\]. However, one should note that in our study most unmarried subjects did not respond to the question on sexual functioning as they may deem it culturally improper to express sexual desires or affairs "*And say to the believing women that they should lower their gaze and guard their modesty; that they should not display their beauty and ornaments except what (must ordinarily) appear thereof"(Sorat Al Noor 24:31, The Holy Quran)*. A similar argument was made in a Moroccan study that clearly described sexual impact in breast cancer as a taboo in the clinical setting \[[@B26]\].

Factors associated with quality of life scores
----------------------------------------------

The lack of an association between age and quality of life as opposed to most \[[@B15],[@B18]\] but not all \[[@B19]\] previous studies could be due to several factors. First, different age groupings were used in the various studies. Second, the questionnaire does not contain questions about specific concerns related to younger women such as fertility and abrupt menopause \[[@B15],[@B24]\], thereby reducing the impact of these issues on quality of life of younger women.

Interestingly, single women had better global quality of life, whereas married women had better physical functioning which is in agreement with some but not all studies \[[@B27],[@B28]\]. One of the reasons may be related to the fact that single women are under less pressure to worry about their partner's opinion because traditionally and religiously the local Islamic society places constraints around dating and premarital sex *"Nor come nigh to adultery: for it is a shameful (deed) and an evil, opening the road (to other evils"(Sorat Al Israa 17:32, The Holy Quran)*. On the other hand, polgyny is still allowed in some Islamic countries including Bahrain, with the specific limitation that a man can have up to four wives at any one time "*Marry women of your choice, Two or three or four; but if you fear that you shall not be able to deal justly (with them), then only one" (Sorat Al Nissa 4:3, The Holy Quran)*. This may be intimidating to some married women who fear that a serious and crippling illness could be an excuse for their husband to take a second wife, especially if the woman was unable to attend to her husband's needs . Married women, however, functioned better physically as they had to continue to do the house work regardless of the disease \[[@B29]\].

Breast conservative surgery (lumpectomy) was not only associated with better global quality of life but also with better physical, role and social functioning as in previous studies \[[@B19],[@B30]\]. Together with recent data about comparable survival time for both procedures in early stage breast cancer \[[@B31]\], this should have an implication on surgeon's and patient's choice of surgery. However, receiving chemotherapy, radiotherapy or hormone therapy was not associated with significant deterioration of quality of life. A significant amount of literature has shown that the impairment in quality of life due to such therapy is minor and limited to short term rather than long term quality of life \[[@B32],[@B33]\].

Long term survivors showed better role functioning, sexual functioning and future perspectives compared to early survivors. On the other hand, early survivors reported more breast symptoms and were more upset by their hair loss. This is expected as the first year is usually the year during which patients receive adjuvant therapy and suffer from its various complications. This is in line with many previous studies which showed that the longer time since diagnosis is, the better the quality of life will be \[[@B18],[@B34]-[@B36]\]. One should note that this study did not compare quality of life of the same individuals at several time intervals but compared different subjects with various time elapsed since diagnosis.

The current study provided important information about Bahraini breast cancer survivors with several strengths including randomized sampling method, use of standardized measures of quality of life, a satisfactory response rate of 71%, and the use of a clinically meaningful analysis. However, it has limitations that should be addressed in future research including lack of a disease-free control group and incomplete clinical information about cancer in the Cancer Registry especially with respect to grade and stage of the disease.

Implications for practice and policy
------------------------------------

The results are important when counseling patients about side effects of the disease and the need for greater attention to cancer related symptoms such as fatigue, pain, insomnia, arm symptoms and hair loss. Furthermore, sexual issues after breast cancer diagnosis and treatment should be addressed and explored in a culturally sensitive way. Due to improved quality of life and comparable survival time, lumpectomy should be considered in all women with early stage disease. Special care and attention should be given to women with metastatic lesions as their quality of life is markedly affected in most quality of life domains. Further research should address cultural differences in issues related to sexuality, body image and interpretation of quality of life as a concept.

Conclusion
==========

Bahraini breast cancer survivors reported favorable overall global quality of life. Bahraini women showed good functioning on most QLQ-C30 functional scales, with the lowest score for emotional functioning. Fatigue, sleep disturbance and pain were the most bothersome symptoms. In the disease specific tool, women reported the lowest performance in sexual enjoyment and functioning whereas arm symptoms and hair loss were among the most severe symptoms reported. Many factors were related to lower global quality of life including marital status, menopausal status, metastases, monthly income and type of surgery performed. Predictors of global health quality of life were staging of the disease and menopausal status whereas metastases predicted physical and role functioning. This study highlights the women at risk of poorer quality of life after breast cancer and the issues that most need to be addressed in this Middle East society.
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